Physician profile
David P Wang
NPI 1386987840
$819.97
in general payments reported to CMS, 2019-2025
14 companies · $208 in 2025
The $208 reported for 2025 was more than what 80% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.27 · 2020: $446 · 2021: $26.02 · 2023: $46.34 · 2024: $48.27 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171.25 | 2020 | |
| Incyte Corporation | $127.21 | 2024-2025 | Opzelura |
| Genzyme Corporation | $97.25 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $95.91 | 2020-2025 | |
| Stemline Therapeutics INC. | $93.85 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.11 | 2020 | |
| Sandoz INC. | $33.94 | 2025 | Hyrimoz |
| Lilly USA, LLC | $28.51 | 2023 | Olumiant, Taltz |
| Janssen Biotech, INC. | $27.11 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.27 | 2024 | Spevigo |
| Leo Pharma INC. | $21.27 | 2020 | |
| Strata Skin Sciences, INC. | $17.83 | 2023 | Xtrac |
| Amgen INC. | $16.77 | 2020 | |
| Myriad Genetic Laboratories, INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.